Pancreatic cancer cells create immune-safe zones to shield tumors

How Pancreatic Tumors Build an Immune-Safe Zone

Pancreatic cancer remains notoriously difficult for the immune system to target because of its complex tumor microenvironment. This dense surrounding area contains scar-like tissue and immunosuppressive cells that prevent T cells from reaching malignant cells or exhaust them before they can launch an effective assault. Researchers at the Icahn School of Medicine at Mount Sinai investigated how specific cancer cells alter this surrounding ecosystem to gain a survival advantage. Using a spatial genomics platform called Perturb-map, the research team analyzed tumor cells with different genetic traits. The analysis showed that cancer cells reorganize their surrounding immune microenvironment before specific clones dominate the tumor population. This indicates that certain cancer cells thrive not simply by growing faster, but by actively modifying their surroundings to make survival easier.

Proteins and Macrophages Drive Immune Suppression

The study identified proteins PAI1 and PAI2 as key organizers of the tumor microenvironment. Both proteins interfere with enzymes responsible for breaking down fibrin. As fibrin clears more slowly, fibrin-rich structures accumulate around the cancer cells, attracting and trapping macrophages. Depending on the signals they receive, these macrophages can either promote or suppress inflammation. Within these tumor niches, macrophages shift into an immunosuppressive state and help clear out cancer-killing T cells. Laboratory models demonstrated that when just 5% of a pancreatic cancer cell population produced PAI1, it was enough to increase immunosuppressive macrophages nearby and reduce activated T cells. This protective effect extended beyond the PAI1-producing cells to encompass surrounding cancer cells as well. Immunosuppression was not distributed evenly throughout the tumor; instead, localized groups of cancer cells established private protection zones.

Targeting Proteins Shrinks Tumors and Restores T Cell Activity

When researchers deleted the genes responsible for producing PAI1 or PAI2 in pancreatic cancer cells, tumor burden in mice dropped by more than half. The genetically modified tumors showed more than double the number of CD8 T cells, alongside an increase in activated, cancer-killing T cells and a clear reduction in exhausted T cells. Removing either PAI1 or PAI2 also improved how pancreatic tumors responded to anti-PD-1 immunotherapy, a treatment that removes molecular brakes on T cells to restore their attack capabilities. The research team subsequently tested an experimental drug, PAI-039, designed to inhibit PAI1. Combining PAI-039 with anti-PD-1 treatment extended survival across two pancreatic cancer models. Blocking the interaction between fibrin and macrophages yielded similar results. The study highlights that cancer-produced proteins, the fibrin-rich environments they create, and the immune cells drawn to those regions could serve as targets for making pancreatic tumors more vulnerable to immune attacks. Because the therapeutic experiments took place in animal models, the research team emphasized that further investigation is required to confirm whether these strategies can be applied safely and effectively in humans.